General Information of Drug Therapeutic Target (DTT) (ID: TTJGY7A)

DTT Name Complement C3 (CO3)
Synonyms C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; C3
Gene Name C3
DTT Type
Clinical trial target
[1]
BioChemical Class
Complement system
UniProt ID
CO3_HUMAN
TTD ID
T26851
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVH
DFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKV
VLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSL
SSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTE
KFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEV
VLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKT
PKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPL
SITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMD
RAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGA
SGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDK
GVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAEL
QCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEAC
KKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKE
PPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVV
RNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVI
VPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKE
DIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTP
TVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTA
YVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKD
MALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMG
RLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQR
YYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLR
SEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDA
KNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSD
RNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDG
KLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDE
YIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSY
IIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN
Function
Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).
KEGG Pathway
Phagosome (hsa04145 )
Complement and coagulation cascades (hsa04610 )
Pertussis (hsa05133 )
Legionellosis (hsa05134 )
Leishmaniasis (hsa05140 )
Chagas disease (American trypanosomiasis) (hsa05142 )
Staphylococcus aureus infection (hsa05150 )
Tuberculosis (hsa05152 )
Herpes simplex infection (hsa05168 )
Viral carcinogenesis (hsa05203 )
Systemic lupus erythematosus (hsa05322 )
Reactome Pathway
Activation of C3 and C5 (R-HSA-174577 )
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933 )
Peptide ligand-binding receptors (R-HSA-375276 )
G alpha (i) signalling events (R-HSA-418594 )
Regulation of Complement cascade (R-HSA-977606 )
Alternative complement activation (R-HSA-173736 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pegcetacoplan DM4HQ52 Paroxysmal nocturnal haemoglobinuria 3A21.0 Approved [1]
------------------------------------------------------------------------------------
4 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imprime PGG DMIUA3M Non-hodgkin lymphoma 2B33.5 Phase 2/3 [2]
AMY-101 DMS0GA6 Gingivitis DA0B Phase 2 [3]
NGM621 DM84DP5 Geographic atrophy 9B75 Phase 2 [4]
POT-4 DMH0LM2 Macular degeneration 9B78.3 Phase 2 [5]
------------------------------------------------------------------------------------
28 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ac-ICV(1MeW)QDWGAHRCT-NH2 DM351NL Discovery agent N.A. Investigative [6]
Ac-ICV(5fW)QDWGAHRCT-NH2 DMQLPGA Discovery agent N.A. Investigative [6]
Ac-ICV(5MeW)QDWGAHRCT-NH2 DM52T90 Discovery agent N.A. Investigative [6]
Ac-ICVWQD(5fW)GAHRCT-NH2 DMPK9LG Discovery agent N.A. Investigative [6]
Ac-ICVWQDWGAHRCT-NH2 DMPSI26 Discovery agent N.A. Investigative [6]
Ac-I[CV(1Nal)QDWGAHRC]T DMJVRPD Discovery agent N.A. Investigative [7]
Ac-I[CV(2Igl)QDWGAHRC]T DM14DEL Discovery agent N.A. Investigative [7]
Ac-I[CV(2Igl)QDWGAHRC]T-NH2 DMQISG6 Discovery agent N.A. Investigative [7]
Ac-I[CV(2Nal)QDWGAHRC]T DM20PEO Discovery agent N.A. Investigative [7]
Ac-I[CV(2Nal)QDWGAHRC]T-NH2 DMX2IRY Discovery agent N.A. Investigative [7]
Ac-I[CV(Bpa)QDWGAHRC]T DMDFKU3 Discovery agent N.A. Investigative [7]
Ac-I[CV(Bpa)QDWGAHRC]T-NH2 DMZG46O Discovery agent N.A. Investigative [7]
Ac-I[CV(Bta)QDWGAHRC]T DM5NMVP Discovery agent N.A. Investigative [7]
Ac-I[CV(Bta)QDWGAHRC]T-NH2 DMFLA5T Discovery agent N.A. Investigative [7]
Ac-I[CV(Dht)QDWGAHRC]T DMO9VWH Discovery agent N.A. Investigative [7]
Ac-I[CV(Yphs)QDWGAHRC]I-NH2 DMY18ET Discovery agent N.A. Investigative [7]
Ac-I[CVFQDWGHHRC]T-NH2 DMFOTYQ Discovery agent N.A. Investigative [7]
Ac-I[CVHQDWGHHRC]T-NH2 DMLU3PZ Discovery agent N.A. Investigative [7]
Ac-I[CVSQDWGHHRC]T-NH2 DMDPSBQ Discovery agent N.A. Investigative [7]
Ac-I[CVTQDWGHHRC]T-NH2 DMNVMB5 Discovery agent N.A. Investigative [7]
Ac-I[CVVQDWGAHRC]T-NH2 DMRSKIY Discovery agent N.A. Investigative [7]
Ac-I[CVWQDWG(Abu)HRC]T-NH2 DMUW3T4 Discovery agent N.A. Investigative [7]
Ac-I[CVWQDWGAHRC]dT DML5ZSJ Discovery agent N.A. Investigative [7]
Ac-I[CVWQDWGAHRC]T DMV3PC7 Discovery agent N.A. Investigative [7]
Ac-I[CVWQDWGHHRC]T-NH2 DMBA1LS Discovery agent N.A. Investigative [7]
Ac-I[CVWQDWGWHRC]T-NH2 DMDIUK6 Discovery agent N.A. Investigative [7]
Ac-I[CVYQDWGAHRC]T-NH2 DM3Q5SU Discovery agent N.A. Investigative [7]
Cysteine Sulfenic Acid DM4GZUJ N. A. N. A. Investigative [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Investigative Drug(s)

References

1 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
2 National Cancer Institute Drug Dictionary (drug id 599816).
3 The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
4 Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 Mar;235:131-142.
5 Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
6 Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.
7 Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.